Chlorpheniramine (maleate)

Chlorpheniramine maleate is a histamine H1 receptor antagonist with an IC50 of 12 nM[1][2][3].

Product Specifications

CAS Number

[113-92-8]

Product Name Alternative

Chlorphenamine maleate

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Histamine Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Immunology/Inflammation; Neuronal Signaling

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Endocrinology

Assay Protocol

https://www.medchemexpress.com/Chlorpheniramine-maleate.html

Concentration

10mM

Purity

99.67

Solubility

DMSO : ≥ 100 mg/mL|H2O : 33.33 mg/mL (ultrasonic)

Smiles

CN(C)CCC(C1=CC=C(Cl)C=C1)C2=CC=CC=N2.O=C(O)/C=C\C(O)=O

Molecular Formula

C20H23ClN2O4

Molecular Weight

390.86

Precautions

H302, H315, H319, H335

References & Citations

[1]Medina, M.A., et al., Chlorpheniramine inhibits the synthesis of ornithine decarboxylase and the proliferation of human breast cancer cell lines. Breast Cancer Res Treat, 1995. 35 (2) : p. 187-94.|[2]Kelly, J.X., et al., Design, synthesis, and evaluation of 10-N-substituted acridones as novel chemosensitizers in Plasmodium falciparum. Antimicrob Agents Chemother, 2007. 51 (11) : p. 4133-40.|[3]Iemura, R., et al., Synthesis of 2- (4-substituted-1-piperazinyl) benzimidazoles as H1-antihistaminic agents. J Med Chem, 1986. 29 (7) : p. 1178-83.|[4]Takano, N., I. Arai, and M. Kurachi, Analysis of the spontaneous scratching behavior by NC/Nga mice: a possible approach to evaluate antipruritics for subjects with atopic dermatitis. Eur J Pharmacol, 2003. 471 (3) : p. 223-8.|[5]Kim J, et al. Inhibitory effects of antihistamines, diphenhydramine and chlorpheniramine, on proton currents in BV2 microglial cells. Eur J Pharmacol. 2017 Mar 5;798:122-128.

Shipping Conditions

Room Temperature

Storage Conditions

4°C (Powder, sealed storage, away from moisture)

Scientific Category

Reference compound1

Clinical Information

Launched

Isoform

H1 Receptor

Citation 01

Chemosphere. 2019 Jun:225:378-387.|J Pharm Sci. 2019 Sep;108 (9) :2895-2904.|J Inflamm Res. 2025 Jun 17:18:7907-7919.|Neuropharmacology. 2025 Nov 1:278:110593.